Gardner Thomas W, Chew Emily Y
aDepartment of Ophthalmology and Visual Sciences, WK Kellogg Eye Center, University of Michigan Medical School, Ann Arbor, MichiganbNational Eye Institute, Bethesda, Maryland, USA.
Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):91-6. doi: 10.1097/MED.0000000000000238.
The risk of vision loss from diabetic retinopathy has fallen dramatically over the past 3 decades with improvements in diabetes and blood pressure treatments, and with advances in laser surgery and intraocular drug delivery. Nevertheless, diabetes continues to be a major cause of blindness. This study summarizes the state of the art in diabetic retinopathy research and provides a perspective on opportunities for future investigations.
New insights into the pathophysiology of diabetes and diabetic retinopathy will improve metabolic control. Structure-function analyses are revealing new details of diabetic retinopathy. Intraocular drug therapy provides improved visual outcomes. Together these steps will yield better means to detect and quantify vision loss, and to develop patient-specific treatments to preserve vision for persons with diabetes.
Retinopathy is one of the most successfully treated complications of diabetes and will continue to be an important area of research for patients and their families.
在过去30年中，随着糖尿病和血压治疗的改善，以及激光手术和眼内药物递送技术的进步，糖尿病视网膜病变导致视力丧失的风险已大幅下降。尽管如此，糖尿病仍是失明的主要原因。本研究总结了糖尿病视网膜病变研究的现状，并对未来研究的机会提供了一个观点。
对糖尿病和糖尿病视网膜病变病理生理学的新见解将改善代谢控制。结构-功能分析揭示了糖尿病视网膜病变的新细节。眼内药物治疗改善了视觉效果。这些措施共同将产生更好的方法来检测和量化视力丧失，并开发针对患者的治疗方法，以保护糖尿病患者的视力。
视网膜病变是糖尿病最成功治疗的并发症之一，仍将是患者及其家属的重要研究领域。
